Erasca, Inc.
ERAS
Kedudukan dalam Saham
#3406
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Harga Saham
$14.56
Modal Pasaran
$5.09B
Perubahan (1 hari)
6.94%
Perubahan (1 tahun)
492.07%
Negara
US
Perdagangan Erasca, Inc. (ERAS)
Kategori
Healthcare
Sejarah pecahan saham untuk Erasca, Inc. (ERAS)
Saham Erasca, Inc. (simbol: ERAS) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Oct 20, 2026.
Satu saham ERAS yang dibeli sebelum Oct 20, 2026 kini bersamaan dengan 0 saham ERAS.
Pecahan saham terkini berlaku pada Oct 20, 2026.
Satu saham ERAS yang dibeli sebelum Oct 20, 2026 kini bersamaan dengan 0 saham ERAS.
Senarai pecahan saham
| Tahun | Pecahan | Gandaan | Gandaan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | |||
Pecahan saham untuk syarikat pesaing atau serupa
| Syarikat | Bilangan pecahan saham | Gandaan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
